Psoriasis
Conditions
Brief summary
The primary objective is based on Week 12 co-primary endpoints of PASI (Psoriasis Area and Severity Index) 75 and sPGA (Static Physician's Global Assessment) 0/1, and overall safety Secondary objectives of Part 1 are to evaluate the efficacy and safety of BI 730357 through 24 weeks of treatment
Interventions
DRUGPlacebo (fasted)
Placebo matching BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks).
DRUGBI 25 mg (fasted)
25 milligram (mg) BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks).
DRUGBI 50 mg (fasted)
50 milligram (mg) BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks).
DRUGBI 100 mg (fasted)
100 milligram (mg) BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks).
DRUGBI 200 mg (fasted)
200 milligram (mg) BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks).
DRUGPlacebo (fed)
4 film-coated tablets of matching Placebo were taken orally in the morning with a meal and 2 film-coated tablets of matching Placebo were taken orally in the evening with a meal for 12 weeks.
DRUGBI 400 mg once daily (fed)
4 film-coated tablets of 100 milligram (mg) BI 730357 (400 mg in total) were taken orally in the morning with a meal and 2 film-coated tablets of matching Placebo were taken orally in the evening with a meal for 12 weeks.
DRUGBI 200 mg twice daily, 400 mg total (fed)
2 film-coated tablets of 100 milligram (mg) BI 730357 were taken orally with a meal in the morning and evening (twice daily; total daily dosage: 400 mg) for 12 weeks.
Sponsors
Boehringer Ingelheim
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Male or female patients. Woman Of Childbearing Potential (WoCBP) must be ready and able to use highly effective methods of birth control per International Conference on Harmonisation (ICH) M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly from date of screening until 4 weeks after last treatment in this trial. A list of contraception methods meeting these criteria is provided in the patient information. * Age 18 to 75 years (both inclusive) at screening * BMI \< 35 kg/m2 at screening * Diagnosis of chronic plaque psoriasis (with or without psoriatic arthritis) for at least 6 months before the first administration of study drug. Duration of diagnosis may be reported by the patient * Patients must be candidates for systemic PsO therapy.Moderate-to-severe plaque psoriasis: * BSA ≥10% and * PASI ≥12 and * sPGA moderate or severe * Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial
Exclusion criteria
* Nonplaque forms of PsO (including guttate, erythrodermic, or pustular), current druginduced PsO (including a new onset or exacerbation of PsO from, e.g., beta blockers, calcium channel blockers, lithium), active ongoing inflammatory diseases (including but not limited to Inflammatory bowel disease (IBD)) other than PsO that might confound trial evaluations * Previous enrolment in this trial or previous exposure to BI 730357. * Current enrollment in another investigational device or drug trial, or is less than 30 days (from randomisation) since ending another investigational device or drug trial(s), or receipt of other investigational treatment(s). * Use of * any biologic agent within 12 weeks, or * any anti IL-23 biologic agent within 24 weeks prior to randomisation, or * systemic anti-psoriatic medications or phototherapy within 4 weeks prior to randomisation, or * topical anti-psoriasis medications within 2 weeks prior to randomisation * Receipt of a live vaccination within 12 weeks prior to randomisation (visit 2), or any plan to receive a live vaccination during the conduct of this trial * Patients who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial * Patients not expected to comply with the protocol requirements or not expected to complete the trial as scheduled. * Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes the patient an unreliable trial participant or unlikely to complete the trial. * Major surgery (major according to the investigator's assessment) performed within 12 weeks prior to randomisation or planned within 12 months after screening, e.g., hip replacement * Women who are pregnant, nursing, or who plan to become pregnant while in the trial * Any documented active or suspected malignancy or history of malignancy within 5 years prior to screening, except appropriately treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ carcinoma of uterine cervix * Relevant chronic or acute infections including human immunodeficiency virus (HIV), viral hepatitis, candidiasis and tuberculosis. A patient can be re-screened if the patient was treated and is cured from the acute infection. * Evidence of a current or previous disease (including known or suspected IBD, and cardiovascular disease), or medical finding that in the opinion of the investigator is clinically significant and would make the study participant unreliable to adhere to the protocol or to complete the trial, compromise the safety of the patient, or compromise the quality of the data. * Any suicidal ideation, including grade 4 or 5 in the Columbia Suicide Severity Rating Scale (CSSRS) in the past 3 months (i.e., active suicidal thought with intent but without specific plan, or active suicidal thought with plan and intent). * Unwillingness to adhere to the rules of UV-light protection * Further
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Patients Who Achieved Psoriasis Area Severity Index Score (PASI) 75 at Week 12 | Assesment at week 12 of treatment | Number of patients who achieved Psoriasis Area Severity Index score (PASI) 75 at week 12. The PASI is a tool which provides a numeric scoring for patients overall psoriasis disease state, ranging from 0 to 72. It is a linear combination of percent of surface area of skin that is affected and the severity of erythema, infiltration, and desquamation over four body regions. Higher scores indicating higher severity, while a score of 0 indicates no disease. PASI 75 is based on the percent reduction from baseline, generally summarized as a dichotomous outcome based on achieving over an 75% reduction. No statistical comparisons were planned or carried out for Part 2 of the trial. |
| Number of Patients Who Achieved a Static Physician's Global Assessment Score of 'Clear' or 'Almost Clear' (sPGA 0/1) at Week 12. | Assesment at week 12 of treatment | Number of patients who achieved a static Physician's Global Assessment score of 'clear' or 'almost clear' (sPGA 0/1) at Week 12. The sPGA used in this trial is a 5 point score ranging from 0 to 4, based on the physician's assessment of the average thickness, erythema, and scaling of all psoriatic lesions. The assessment is considered static which refers to the patients disease state at the time of the assessments, without comparison to any of the subject's previous disease states, whether at Baseline or at a previous visit. A lower score indicates less body coverage, with 0 being clear and 1 being almost clear. No statistical comparisons were planned or carried out for Part 2 of the trial. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Patients Who Achieved Psoriasis Area Severity Index Score (PASI) 100 at Week 12 | Assesment at week 12 of treatment | Number of patients who achieved Psoriasis Area Severity Index score (PASI) 100 at week 12. The PASI is a tool which provides a numeric scoring for patients overall psoriasis disease state, ranging from 0 to 72. It is a linear combination of percent of surface area of skin that is affected and the severity of erythema, infiltration, and desquamation over four body regions. Higher scores indicating higher severity, while a score of 0 indicates no disease. PASI 100 is based on the percent reduction from baseline, generally summarized as a dichotomous outcome based on achieving over an 100% reduction. No statistical comparisons were planned or carried out for Part 2 of the trial. Statistical analysis could not be performed for arms with 0 participants reaching PASI 100. |
| Number of Patients Who Achieved Psoriasis Area Severity Index Score (PASI) 75 at Weeks 16, 20, and 24 | Assesment at week 16, 20 and 24 of treatment | Number of patients who achieved Psoriasis Area Severity Index score (PASI) 75 at weeks 16, 20 and 24. The PASI is a tool which provides a numeric scoring for patients overall psoriasis disease state, ranging from 0 to 72. It is a linear combination of percent of surface area of skin that is affected and the severity of erythema, infiltration, and desquamation over four body regions. Higher scores indicating higher severity, while a score of 0 indicates no disease. PASI 75 is based on the percent reduction from baseline, generally summarized as a dichotomous outcome based on achieving over an 75% reduction. |
| Number of Patients Who Achieved a Static Physician's Global Assessment Score of 'Clear' (sPGA 0) at Week 12 | Assesment at week 12 of treatment | Number of patients who achieved a static Physician's Global Assessment score of 'clear' (sPGA 0) at Week 12. The sPGA used in this trial is a 5 point score ranging from 0 to 4, based on the physician's assessment of the average thickness, erythema, and scaling of all psoriatic lesions. The assessment is considered static which refers to the patients disease state at the time of the assessments, without comparison to any of the subject's previous disease states, whether at Baseline or at a previous visit. A lower score indicates less body coverage, with 0 being clear and 1 being almost clear. No statistical comparisons were planned or carried out for Part 2 of the trial. |
| Number of Patients Who Achieved Psoriasis Area Severity Index Score (PASI) 50 at Week 12 | Assesment at week 12 of treatment | Number of patients who achieved Psoriasis Area Severity Index score (PASI) 50 at week 12. The PASI is a tool which provides a numeric scoring for patients overall psoriasis disease state, ranging from 0 to 72. It is a linear combination of percent of surface area of skin that is affected and the severity of erythema, infiltration, and desquamation over four body regions. Higher scores indicating higher severity, while a score of 0 indicates no disease. PASI 50 is based on the percent reduction from baseline, generally summarized as a dichotomous outcome based on achieving over an 50% reduction. No hypothesis testing was planned or carried out for Part II. |
| Overall Change From Baseline in Psoriasis Symptoms Evaluated Using the Total Score of the Psoriasis Symptoms Scale (PSS) at Week 12 | Assesment at week 12 of treatment | Overall change from baseline in psoriasis symptoms evaluated using the total score of the Psoriasis Symptoms Scale (PSS) at Week 12. The PSS is a four-item patient-reported outcome (PRO) instrument that assesses the severity of psoriasis symptoms in patients with moderate to severe psoriasis. The symptoms included are: pain, redness, itching and burning from psoriasis. Current symptom severity is assessed for a 24 hour recall period using a 5-point verbal rating scale, the PSS score ranges from 0 (none) to 4 (very severe). The symptom scores are added to an unweighted total score (range: 0 to 16). Presented 'Mean' values are actually 'Adjusted Mean'. No hypothesis testing was planned or carried out for Part II. |
| Number of Patients Who Achieved a Dermatology Life Quality Index Score of 'no Effect on Patient's Life' (DLQI 0/1) at Week 12 | Assesment at week 12 of treatment | Number of patients who achieved a Dermatology Life Quality Index score of 'no effect on patient's life' (DLQI 0/1) at Week 12. The DLQI is a subject-administered, ten-question, quality of life questionnaire covering 6 domains including symptoms and feelings, daily activities, leisure, work and school, personal relationships and treatment. Item scores range from 0 (not relevant/not at all) to 3 (very much). Question 7 is a yes/ no question where yes is scored as 3. DLQI total score is calculated by summing the scores of each question resulting in a range of 0 to 30 where 0-1 = no effect on subject's life, 2-5 = small effect, 6-10 = moderate effect, 11-20 = very large effect, and 21-30 = extremely large effect on subject's life. The higher the score, the more the quality of life is impaired. A 4-point change from baseline is considered a clinically important difference. No hypothesis testing was planned or carried out for Part II. |
| Number of Patients Who Achieved a Static Physician's Global Assessment Score of 'Clear' or 'Almost Clear' (sPGA 0/1) at Weeks 16, 20, and 24 | Assesment at week 16, 20 and 24 of treatment | Number of patients who achieved a static Physician's Global Assessment score of 'clear' or 'almost clear' (sPGA 0/1) at Week 16, 20 and 24. The sPGA used in this trial is a 5 point score ranging from 0 to 4, based on the physician's assessment of the average thickness, erythema, and scaling of all psoriatic lesions. The assessment is considered static which refers to the patients disease state at the time of the assessments, without comparison to any of the subject's previous disease states, whether at Baseline or at a previous visit. A lower score indicates less body coverage, with 0 being clear and 1 being almost clear. |
| Number of Patients Who Achieved Psoriasis Area Severity Index Score (PASI) 90 at Week 12 | Assesment at week 12 of treatment | Number of patients who achieved Psoriasis Area Severity Index score (PASI) 90 at week 12. The PASI is a tool which provides a numeric scoring for patients overall psoriasis disease state, ranging from 0 to 72. It is a linear combination of percent of surface area of skin that is affected and the severity of erythema, infiltration, and desquamation over four body regions. Higher scores indicating higher severity, while a score of 0 indicates no disease. PASI 90 is based on the percent reduction from baseline, generally summarized as a dichotomous outcome based on achieving over an 90% reduction. No statistical comparisons were planned or carried out for Part 2 of the trial. Statistical analysis could not be performed for arms with 0 participants reaching PASI 90. |
Countries
Canada, Germany, United States
Participant flow
Recruitment details
This trial was a 2-part, randomised, placebo-controlled, double-blind, parallel-group, dose-ranging trial to investigate the efficacy, safety, and tolerability of different dose regimens of BI 730357 in patients with moderate-to-severe plaque psoriasis.
Pre-assignment details
All subjects were screened for eligibility prior to participation in the trial. Subjects attended a specialist site which ensured that they (the subjects) strictly met all inclusion and none of the exclusion criteria. Subjects were not to be allocated to a treatment group if any of the entry criteria were violated.
Participants by arm
| Arm | Count |
|---|---|
| Part I - Placebo (Fasted) Part I - Placebo matching BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks). Participants who failed to achieve a Psoriasis Area Severity Index score (PASI) 75 response at Week 12 were switched to a 200 mg dose, participants switching dose were imputed as failure for records after week 12, under original randomized treatment arm. | 20 |
| Part I - BI 25 mg (Fasted) Part I - 25 milligram (mg) BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks). Participants who failed to achieve a Psoriasis Area Severity Index score (PASI) 50 response at Week 12 were switched to a 50 mg dose, participants switching dose were imputed as failure for records after week 12, under original randomized treatment arm. | 40 |
| Part I - BI 50 mg (Fasted) Part I - 50 milligram (mg) BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks). Participants who failed to achieve a Psoriasis Area Severity Index score (PASI) 50 response at Week 12 were switched to a 100 mg dose, participants switching dose were imputed as failure for records after week 12, under original randomized treatment arm. | 39 |
| Part I - BI 100 mg (Fasted) Part I - 100 milligram (mg) BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks). Participants who failed to achieve a Psoriasis Area Severity Index score (PASI) 50 response at Week 12 were switched to a 200 mg dose, participants switching dose were imputed as failure for records after week 12, under original randomized treatment arm. | 39 |
| Part I - BI 200 mg (Fasted) Part I - 200 milligram (mg) BI 730357 taken orally once daily as a film-coated tablet in the morning while fasted for 12 weeks in period 1 followed by the same treatment for 12 weeks in period 2 (total treatment period of 24 weeks). | 40 |
| Part II - Placebo (Fed) Part II - 4 film-coated tablets of matching Placebo were taken orally in the morning with a meal and 2 film-coated tablets of matching Placebo were taken orally in the evening with a meal for 12 weeks. | 10 |
| Part II - BI 400 mg Once Daily (Fed) Part II - 4 film-coated tablets of 100 milligram (mg) BI 730357 (400 mg in total) were taken orally in the morning with a meal and 2 film-coated tablets of matching Placebo were taken orally in the evening with a meal for 12 weeks. | 43 |
| Part II - BI 200 mg Twice Daily, 400 mg Total (Fed) Part II - 2 film-coated tablets of 100 milligram (mg) BI 730357 were taken orally with a meal in the morning and evening (twice daily; total daily dosage: 400 mg) for 12 weeks. | 42 |
| Total | 273 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 | FG006 | FG007 |
|---|---|---|---|---|---|---|---|---|---|
| Eligible for Period 2 | Switch to higher dose at end of period 1 | 15 | 35 | 21 | 25 | 0 | 0 | 0 | 0 |
| Not Eligible for Period 2 | Part II subjects did not have a period 2. | 0 | 0 | 0 | 0 | 0 | 9 | 40 | 40 |
| Not Eligible for Period 2 | Pregnancy | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Not Eligible for Period 2 | Withdrawal by Subject | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Period 1 | Adverse Event | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Period 1 | History of suicidal ideation | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Period 1 | Lost to Follow-up | 0 | 0 | 1 | 2 | 1 | 0 | 1 | 2 |
| Period 1 | Protocol Violation | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Period 1 | pursue other treatment options | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Period 1 | Withdrawal by Subject | 3 | 3 | 5 | 2 | 2 | 0 | 3 | 0 |
| Period 2 | Adverse Event | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 |
| Period 2 | Lost to Follow-up | 0 | 0 | 1 | 0 | 4 | 0 | 0 | 0 |
| Period 2 | Withdrawal by Subject | 0 | 0 | 7 | 4 | 7 | 0 | 0 | 0 |
Baseline characteristics
| Characteristic | Part I - BI 25 mg (Fasted) | Part I - Placebo (Fasted) | Total | Part II - BI 200 mg Twice Daily, 400 mg Total (Fed) | Part II - BI 400 mg Once Daily (Fed) | Part II - Placebo (Fed) | Part I - BI 200 mg (Fasted) | Part I - BI 100 mg (Fasted) | Part I - BI 50 mg (Fasted) |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | 47.2 years STANDARD_DEVIATION 13.7 | 48.1 years STANDARD_DEVIATION 14.7 | 45.8 years STANDARD_DEVIATION 13.9 | 43.7 years STANDARD_DEVIATION 11.5 | 44.1 years STANDARD_DEVIATION 14.7 | 51.6 years STANDARD_DEVIATION 16.3 | 43.8 years STANDARD_DEVIATION 13.1 | 47.6 years STANDARD_DEVIATION 14.4 | 46.3 years STANDARD_DEVIATION 15.1 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 9 Participants | 4 Participants | 62 Participants | 11 Participants | 11 Participants | 2 Participants | 7 Participants | 10 Participants | 8 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 31 Participants | 16 Participants | 211 Participants | 31 Participants | 32 Participants | 8 Participants | 33 Participants | 29 Participants | 31 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Psoriasis Area Severity Index score (PASI) | 17.4 Score on scale STANDARD_DEVIATION 6.2 | 17.1 Score on scale STANDARD_DEVIATION 5.2 | 17.9 Score on scale STANDARD_DEVIATION 6.3 | 17.9 Score on scale STANDARD_DEVIATION 7.4 | 18.8 Score on scale STANDARD_DEVIATION 7.1 | 17.8 Score on scale STANDARD_DEVIATION 5.4 | 16.8 Score on scale STANDARD_DEVIATION 6.6 | 18.6 Score on scale STANDARD_DEVIATION 6 | 18.3 Score on scale STANDARD_DEVIATION 4.8 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 1 Participants | 3 Participants | 20 Participants | 4 Participants | 5 Participants | 1 Participants | 1 Participants | 3 Participants | 2 Participants |
| Race (NIH/OMB) Black or African American | 2 Participants | 1 Participants | 20 Participants | 4 Participants | 5 Participants | 1 Participants | 2 Participants | 2 Participants | 3 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 1 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 37 Participants | 16 Participants | 230 Participants | 33 Participants | 33 Participants | 7 Participants | 37 Participants | 34 Participants | 33 Participants |
| Sex: Female, Male Female | 15 Participants | 4 Participants | 84 Participants | 16 Participants | 6 Participants | 3 Participants | 14 Participants | 12 Participants | 14 Participants |
| Sex: Female, Male Male | 25 Participants | 16 Participants | 189 Participants | 26 Participants | 37 Participants | 7 Participants | 26 Participants | 27 Participants | 25 Participants |
| Static Physician's Global Assessment score (sPGA) Moderate | 35 Participants | 16 Participants | 219 Participants | 34 Participants | 34 Participants | 7 Participants | 30 Participants | 34 Participants | 29 Participants |
| Static Physician's Global Assessment score (sPGA) Severe | 5 Participants | 4 Participants | 54 Participants | 8 Participants | 9 Participants | 3 Participants | 10 Participants | 5 Participants | 10 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk | EG008 affected / at risk | EG009 affected / at risk | EG010 affected / at risk | EG011 affected / at risk | EG012 affected / at risk | EG013 affected / at risk | EG014 affected / at risk | EG015 affected / at risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 5 | 0 / 3 | 0 / 8 | 0 / 6 | 0 / 3 | 0 / 15 | 0 / 2 | 0 / 35 | 0 / 10 | 0 / 21 | 0 / 8 | 0 / 25 | 0 / 37 | 0 / 10 | 0 / 44 | 0 / 42 |
| other Total, other adverse events | 4 / 5 | 2 / 3 | 2 / 8 | 2 / 6 | 3 / 3 | 9 / 15 | 1 / 2 | 15 / 35 | 7 / 10 | 13 / 21 | 7 / 8 | 12 / 25 | 18 / 37 | 5 / 10 | 9 / 44 | 8 / 42 |
| serious Total, serious adverse events | 0 / 5 | 0 / 3 | 0 / 8 | 0 / 6 | 0 / 3 | 0 / 15 | 0 / 2 | 2 / 35 | 0 / 10 | 1 / 21 | 0 / 8 | 0 / 25 | 0 / 37 | 0 / 10 | 0 / 44 | 0 / 42 |
Outcome results
Primary
Number of Patients Who Achieved a Static Physician's Global Assessment Score of 'Clear' or 'Almost Clear' (sPGA 0/1) at Week 12.
Number of patients who achieved a static Physician's Global Assessment score of 'clear' or 'almost clear' (sPGA 0/1) at Week 12. The sPGA used in this trial is a 5 point score ranging from 0 to 4, based on the physician's assessment of the average thickness, erythema, and scaling of all psoriatic lesions. The assessment is considered static which refers to the patients disease state at the time of the assessments, without comparison to any of the subject's previous disease states, whether at Baseline or at a previous visit. A lower score indicates less body coverage, with 0 being clear and 1 being almost clear. No statistical comparisons were planned or carried out for Part 2 of the trial.
Time frame: Assesment at week 12 of treatment
Population: Full Analysis Set (FAS): The FAS includes all patients who received at least 1 dose of trial medication and provided baseline and at least 1 post-randomisation measurement of Psoriasis Area Severity Index (PASI). Subjects with missing data for subsequent visits were included but those entries were imputed as failures.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Part I - Placebo (Fasted) | Number of Patients Who Achieved a Static Physician's Global Assessment Score of 'Clear' or 'Almost Clear' (sPGA 0/1) at Week 12. | 0 Participants |
| Part I - BI 25 mg (Fasted) | Number of Patients Who Achieved a Static Physician's Global Assessment Score of 'Clear' or 'Almost Clear' (sPGA 0/1) at Week 12. | 1 Participants |
| Part I - BI 50 mg (Fasted) | Number of Patients Who Achieved a Static Physician's Global Assessment Score of 'Clear' or 'Almost Clear' (sPGA 0/1) at Week 12. | 3 Participants |
| Part I - BI 100 mg (Fasted) | Number of Patients Who Achieved a Static Physician's Global Assessment Score of 'Clear' or 'Almost Clear' (sPGA 0/1) at Week 12. | 2 Participants |
| Part I - BI 200 mg (Fasted) | Number of Patients Who Achieved a Static Physician's Global Assessment Score of 'Clear' or 'Almost Clear' (sPGA 0/1) at Week 12. | 11 Participants |
| Part II - Placebo (Fed) | Number of Patients Who Achieved a Static Physician's Global Assessment Score of 'Clear' or 'Almost Clear' (sPGA 0/1) at Week 12. | 0 Participants |
| Part II - BI 400 mg Once Daily (Fed) | Number of Patients Who Achieved a Static Physician's Global Assessment Score of 'Clear' or 'Almost Clear' (sPGA 0/1) at Week 12. | 11 Participants |
| Part II - BI 200 mg Twice Daily, 400 mg Total (Fed) | Number of Patients Who Achieved a Static Physician's Global Assessment Score of 'Clear' or 'Almost Clear' (sPGA 0/1) at Week 12. | 10 Participants |
p-value: 0.475895% CI: [-2.3, 7.3]Chi-squared
p-value: 0.20395% CI: [-0.7, 16.1]Chi-squared
p-value: 0.302895% CI: [-1.8, 12.1]Chi-squared
p-value: 0.009595% CI: [13.7, 41.3]Chi-squared
p-value: 0.0007MCPMod Linear model fit.
p-value: 0.0023MCPMod Logistic model fit.
p-value: 0.0018MCPMod Emax1 model fit.
p-value: 0.0386MCPMod Emax2 model fit.
p-value: 0.0004MCPMod Exponential model fit.
Primary
Number of Patients Who Achieved Psoriasis Area Severity Index Score (PASI) 75 at Week 12
Number of patients who achieved Psoriasis Area Severity Index score (PASI) 75 at week 12. The PASI is a tool which provides a numeric scoring for patients overall psoriasis disease state, ranging from 0 to 72. It is a linear combination of percent of surface area of skin that is affected and the severity of erythema, infiltration, and desquamation over four body regions. Higher scores indicating higher severity, while a score of 0 indicates no disease. PASI 75 is based on the percent reduction from baseline, generally summarized as a dichotomous outcome based on achieving over an 75% reduction. No statistical comparisons were planned or carried out for Part 2 of the trial.
Time frame: Assesment at week 12 of treatment
Population: Full Analysis Set (FAS): The FAS includes all patients who received at least 1 dose of trial medication and provided baseline and at least 1 post-randomisation measurement of Psoriasis Area Severity Index (PASI). Subjects with missing data for subsequent visits were included but those entries were imputed as failures.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Part I - Placebo (Fasted) | Number of Patients Who Achieved Psoriasis Area Severity Index Score (PASI) 75 at Week 12 | 0 Participants |
| Part I - BI 25 mg (Fasted) | Number of Patients Who Achieved Psoriasis Area Severity Index Score (PASI) 75 at Week 12 | 2 Participants |
| Part I - BI 50 mg (Fasted) | Number of Patients Who Achieved Psoriasis Area Severity Index Score (PASI) 75 at Week 12 | 3 Participants |
| Part I - BI 100 mg (Fasted) | Number of Patients Who Achieved Psoriasis Area Severity Index Score (PASI) 75 at Week 12 | 4 Participants |
| Part I - BI 200 mg (Fasted) | Number of Patients Who Achieved Psoriasis Area Severity Index Score (PASI) 75 at Week 12 | 12 Participants |
| Part II - Placebo (Fed) | Number of Patients Who Achieved Psoriasis Area Severity Index Score (PASI) 75 at Week 12 | 0 Participants |
| Part II - BI 400 mg Once Daily (Fed) | Number of Patients Who Achieved Psoriasis Area Severity Index Score (PASI) 75 at Week 12 | 11 Participants |
| Part II - BI 200 mg Twice Daily, 400 mg Total (Fed) | Number of Patients Who Achieved Psoriasis Area Severity Index Score (PASI) 75 at Week 12 | 10 Participants |
p-value: 0.309195% CI: [-1.8, 11.8]Chi-squared
p-value: 0.20395% CI: [-0.7, 16.1]Chi-squared
p-value: 0.13895% CI: [0.7, 19.8]Chi-squared
p-value: 0.006295% CI: [15.8, 44.2]Chi-squared
Comparison: The 95% confidence interval for the unadjusted absolute difference in proportion (%) between active group and placebo group was estimated by Chi-square method. As pre-specified, no hypothesis testing was carried out for Part 2 of this trial and no p-values were provided.95% CI: [12.5, 38.6]
Comparison: The 95% confidence interval for the unadjusted absolute difference in proportion (%) between active group and placebo group was estimated by Chi-square method. As pre-specified, no hypothesis testing was carried out for Part 2 of this trial and no p-values were provided.95% CI: [10.9, 36.7]
p-value: 0.0004MCPMod Linear model fit.
p-value: 0.0012MCPMod Logistic model fit.
p-value: 0.0008MCPMod Emax1 model fit.
p-value: 0.0217MCPMod Emax2 model fit.
p-value: 0.0004MCPMod Exponential model fit.
Secondary
Number of Patients Who Achieved a Dermatology Life Quality Index Score of 'no Effect on Patient's Life' (DLQI 0/1) at Week 12
Number of patients who achieved a Dermatology Life Quality Index score of 'no effect on patient's life' (DLQI 0/1) at Week 12. The DLQI is a subject-administered, ten-question, quality of life questionnaire covering 6 domains including symptoms and feelings, daily activities, leisure, work and school, personal relationships and treatment. Item scores range from 0 (not relevant/not at all) to 3 (very much). Question 7 is a yes/ no question where yes is scored as 3. DLQI total score is calculated by summing the scores of each question resulting in a range of 0 to 30 where 0-1 = no effect on subject's life, 2-5 = small effect, 6-10 = moderate effect, 11-20 = very large effect, and 21-30 = extremely large effect on subject's life. The higher the score, the more the quality of life is impaired. A 4-point change from baseline is considered a clinically important difference. No hypothesis testing was planned or carried out for Part II.
Time frame: Assesment at week 12 of treatment
Population: Full Analysis Set (FAS): All patients who received at least 1 dose of trial medication and provided a baseline and at least 1 postrandomisation measurement of PASI. Subjects with missing data for subsequent visits were included but those entries were imputed as failures.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Part I - Placebo (Fasted) | Number of Patients Who Achieved a Dermatology Life Quality Index Score of 'no Effect on Patient's Life' (DLQI 0/1) at Week 12 | 1 Participants |
| Part I - BI 25 mg (Fasted) | Number of Patients Who Achieved a Dermatology Life Quality Index Score of 'no Effect on Patient's Life' (DLQI 0/1) at Week 12 | 3 Participants |
| Part I - BI 50 mg (Fasted) | Number of Patients Who Achieved a Dermatology Life Quality Index Score of 'no Effect on Patient's Life' (DLQI 0/1) at Week 12 | 3 Participants |
| Part I - BI 100 mg (Fasted) | Number of Patients Who Achieved a Dermatology Life Quality Index Score of 'no Effect on Patient's Life' (DLQI 0/1) at Week 12 | 3 Participants |
| Part I - BI 200 mg (Fasted) | Number of Patients Who Achieved a Dermatology Life Quality Index Score of 'no Effect on Patient's Life' (DLQI 0/1) at Week 12 | 8 Participants |
| Part II - Placebo (Fed) | Number of Patients Who Achieved a Dermatology Life Quality Index Score of 'no Effect on Patient's Life' (DLQI 0/1) at Week 12 | 2 Participants |
| Part II - BI 400 mg Once Daily (Fed) | Number of Patients Who Achieved a Dermatology Life Quality Index Score of 'no Effect on Patient's Life' (DLQI 0/1) at Week 12 | 12 Participants |
| Part II - BI 200 mg Twice Daily, 400 mg Total (Fed) | Number of Patients Who Achieved a Dermatology Life Quality Index Score of 'no Effect on Patient's Life' (DLQI 0/1) at Week 12 | 11 Participants |
p-value: 0.714495% CI: [-10.1, 15.1]Chi-squared
p-value: 0.69795% CI: [-10, 15.4]Chi-squared
p-value: 0.69795% CI: [-10, 15.4]Chi-squared
p-value: 0.12595% CI: [-0.6, 30.6]Chi-squared
Comparison: The 95% confidence interval for the unadjusted absolute difference in proportion (%) between active group and placebo group was estimated by Chi-square method. As pre-specified, no hypothesis testing was carried out for Part 2 of this trial and no p-values were provided.95% CI: [-20.3, 36.1]
Comparison: The 95% confidence interval for the unadjusted absolute difference in proportion (%) between active group and placebo group was estimated by Chi-square method. As pre-specified, no hypothesis testing was carried out for Part 2 of this trial and no p-values were provided.95% CI: [-21.9, 34.3]
Secondary
Number of Patients Who Achieved a Static Physician's Global Assessment Score of 'Clear' or 'Almost Clear' (sPGA 0/1) at Weeks 16, 20, and 24
Number of patients who achieved a static Physician's Global Assessment score of 'clear' or 'almost clear' (sPGA 0/1) at Week 16, 20 and 24. The sPGA used in this trial is a 5 point score ranging from 0 to 4, based on the physician's assessment of the average thickness, erythema, and scaling of all psoriatic lesions. The assessment is considered static which refers to the patients disease state at the time of the assessments, without comparison to any of the subject's previous disease states, whether at Baseline or at a previous visit. A lower score indicates less body coverage, with 0 being clear and 1 being almost clear.
Time frame: Assesment at week 16, 20 and 24 of treatment
Population: Full Analysis Set (FAS): The FAS includes all patients who received at least 1 dose of trial medication and provided baseline and at least 1 post-randomisation measurement of Psoriasis Area Severity Index (PASI). Subjects with missing data for subsequent visits were included but those entries were imputed as failures.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part I - Placebo (Fasted) | Number of Patients Who Achieved a Static Physician's Global Assessment Score of 'Clear' or 'Almost Clear' (sPGA 0/1) at Weeks 16, 20, and 24 | Week 16 | 0 Participants |
| Part I - Placebo (Fasted) | Number of Patients Who Achieved a Static Physician's Global Assessment Score of 'Clear' or 'Almost Clear' (sPGA 0/1) at Weeks 16, 20, and 24 | Week 24 | 0 Participants |
| Part I - Placebo (Fasted) | Number of Patients Who Achieved a Static Physician's Global Assessment Score of 'Clear' or 'Almost Clear' (sPGA 0/1) at Weeks 16, 20, and 24 | Week 20 | 0 Participants |
| Part I - BI 25 mg (Fasted) | Number of Patients Who Achieved a Static Physician's Global Assessment Score of 'Clear' or 'Almost Clear' (sPGA 0/1) at Weeks 16, 20, and 24 | Week 20 | 1 Participants |
| Part I - BI 25 mg (Fasted) | Number of Patients Who Achieved a Static Physician's Global Assessment Score of 'Clear' or 'Almost Clear' (sPGA 0/1) at Weeks 16, 20, and 24 | Week 16 | 1 Participants |
| Part I - BI 25 mg (Fasted) | Number of Patients Who Achieved a Static Physician's Global Assessment Score of 'Clear' or 'Almost Clear' (sPGA 0/1) at Weeks 16, 20, and 24 | Week 24 | 1 Participants |
| Part I - BI 50 mg (Fasted) | Number of Patients Who Achieved a Static Physician's Global Assessment Score of 'Clear' or 'Almost Clear' (sPGA 0/1) at Weeks 16, 20, and 24 | Week 20 | 4 Participants |
| Part I - BI 50 mg (Fasted) | Number of Patients Who Achieved a Static Physician's Global Assessment Score of 'Clear' or 'Almost Clear' (sPGA 0/1) at Weeks 16, 20, and 24 | Week 16 | 2 Participants |
| Part I - BI 50 mg (Fasted) | Number of Patients Who Achieved a Static Physician's Global Assessment Score of 'Clear' or 'Almost Clear' (sPGA 0/1) at Weeks 16, 20, and 24 | Week 24 | 3 Participants |
| Part I - BI 100 mg (Fasted) | Number of Patients Who Achieved a Static Physician's Global Assessment Score of 'Clear' or 'Almost Clear' (sPGA 0/1) at Weeks 16, 20, and 24 | Week 16 | 3 Participants |
| Part I - BI 100 mg (Fasted) | Number of Patients Who Achieved a Static Physician's Global Assessment Score of 'Clear' or 'Almost Clear' (sPGA 0/1) at Weeks 16, 20, and 24 | Week 24 | 4 Participants |
| Part I - BI 100 mg (Fasted) | Number of Patients Who Achieved a Static Physician's Global Assessment Score of 'Clear' or 'Almost Clear' (sPGA 0/1) at Weeks 16, 20, and 24 | Week 20 | 2 Participants |
| Part I - BI 200 mg (Fasted) | Number of Patients Who Achieved a Static Physician's Global Assessment Score of 'Clear' or 'Almost Clear' (sPGA 0/1) at Weeks 16, 20, and 24 | Week 20 | 10 Participants |
| Part I - BI 200 mg (Fasted) | Number of Patients Who Achieved a Static Physician's Global Assessment Score of 'Clear' or 'Almost Clear' (sPGA 0/1) at Weeks 16, 20, and 24 | Week 16 | 12 Participants |
| Part I - BI 200 mg (Fasted) | Number of Patients Who Achieved a Static Physician's Global Assessment Score of 'Clear' or 'Almost Clear' (sPGA 0/1) at Weeks 16, 20, and 24 | Week 24 | 13 Participants |
p-value: 0.475895% CI: [-2.3, 7.3]Chi-squared
p-value: 0.302895% CI: [-1.8, 12.1]Chi-squared
p-value: 0.20395% CI: [-0.7, 16.1]Chi-squared
p-value: 0.006295% CI: [15.8, 44.2]Chi-squared
p-value: 0.13895% CI: [0.7, 19.8]Chi-squared
p-value: 0.302895% CI: [-1.8, 12.1]Chi-squared
p-value: 0.014395% CI: [11.6, 38.4]Chi-squared
p-value: 0.20395% CI: [-0.7, 16.1]Chi-squared
p-value: 0.13895% CI: [0.7, 19.8]Chi-squared
p-value: 0.00495% CI: [18, 47]Chi-squared
Secondary
Number of Patients Who Achieved a Static Physician's Global Assessment Score of 'Clear' (sPGA 0) at Week 12
Number of patients who achieved a static Physician's Global Assessment score of 'clear' (sPGA 0) at Week 12. The sPGA used in this trial is a 5 point score ranging from 0 to 4, based on the physician's assessment of the average thickness, erythema, and scaling of all psoriatic lesions. The assessment is considered static which refers to the patients disease state at the time of the assessments, without comparison to any of the subject's previous disease states, whether at Baseline or at a previous visit. A lower score indicates less body coverage, with 0 being clear and 1 being almost clear. No statistical comparisons were planned or carried out for Part 2 of the trial.
Time frame: Assesment at week 12 of treatment
Population: Full Analysis Set (FAS): The FAS includes all patients who received at least 1 dose of trial medication and provided baseline and at least 1 post-randomisation measurement of Psoriasis Area Severity Index (PASI). Subjects with missing data for subsequent visits were included but those entries were imputed as failures.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Part I - Placebo (Fasted) | Number of Patients Who Achieved a Static Physician's Global Assessment Score of 'Clear' (sPGA 0) at Week 12 | 0 Participants |
| Part I - BI 25 mg (Fasted) | Number of Patients Who Achieved a Static Physician's Global Assessment Score of 'Clear' (sPGA 0) at Week 12 | 0 Participants |
| Part I - BI 50 mg (Fasted) | Number of Patients Who Achieved a Static Physician's Global Assessment Score of 'Clear' (sPGA 0) at Week 12 | 0 Participants |
| Part I - BI 100 mg (Fasted) | Number of Patients Who Achieved a Static Physician's Global Assessment Score of 'Clear' (sPGA 0) at Week 12 | 1 Participants |
| Part I - BI 200 mg (Fasted) | Number of Patients Who Achieved a Static Physician's Global Assessment Score of 'Clear' (sPGA 0) at Week 12 | 2 Participants |
| Part II - Placebo (Fed) | Number of Patients Who Achieved a Static Physician's Global Assessment Score of 'Clear' (sPGA 0) at Week 12 | 0 Participants |
| Part II - BI 400 mg Once Daily (Fed) | Number of Patients Who Achieved a Static Physician's Global Assessment Score of 'Clear' (sPGA 0) at Week 12 | 1 Participants |
| Part II - BI 200 mg Twice Daily, 400 mg Total (Fed) | Number of Patients Who Achieved a Static Physician's Global Assessment Score of 'Clear' (sPGA 0) at Week 12 | 1 Participants |
p-value: 0.470195% CI: [-2.4, 7.5]Chi-squared
p-value: 0.309195% CI: [-1.8, 11.8]Chi-squared
Secondary
Number of Patients Who Achieved Psoriasis Area Severity Index Score (PASI) 100 at Week 12
Number of patients who achieved Psoriasis Area Severity Index score (PASI) 100 at week 12. The PASI is a tool which provides a numeric scoring for patients overall psoriasis disease state, ranging from 0 to 72. It is a linear combination of percent of surface area of skin that is affected and the severity of erythema, infiltration, and desquamation over four body regions. Higher scores indicating higher severity, while a score of 0 indicates no disease. PASI 100 is based on the percent reduction from baseline, generally summarized as a dichotomous outcome based on achieving over an 100% reduction. No statistical comparisons were planned or carried out for Part 2 of the trial. Statistical analysis could not be performed for arms with 0 participants reaching PASI 100.
Time frame: Assesment at week 12 of treatment
Population: Full Analysis Set (FAS): The FAS includes all patients who received at least 1 dose of trial medication and provided baseline and at least 1 post-randomisation measurement of Psoriasis Area Severity Index (PASI). Subjects with missing data for subsequent visits were included but those entries were imputed as failures.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Part I - Placebo (Fasted) | Number of Patients Who Achieved Psoriasis Area Severity Index Score (PASI) 100 at Week 12 | 0 Participants |
| Part I - BI 25 mg (Fasted) | Number of Patients Who Achieved Psoriasis Area Severity Index Score (PASI) 100 at Week 12 | 0 Participants |
| Part I - BI 50 mg (Fasted) | Number of Patients Who Achieved Psoriasis Area Severity Index Score (PASI) 100 at Week 12 | 0 Participants |
| Part I - BI 100 mg (Fasted) | Number of Patients Who Achieved Psoriasis Area Severity Index Score (PASI) 100 at Week 12 | 1 Participants |
| Part I - BI 200 mg (Fasted) | Number of Patients Who Achieved Psoriasis Area Severity Index Score (PASI) 100 at Week 12 | 2 Participants |
| Part II - Placebo (Fed) | Number of Patients Who Achieved Psoriasis Area Severity Index Score (PASI) 100 at Week 12 | 0 Participants |
| Part II - BI 400 mg Once Daily (Fed) | Number of Patients Who Achieved Psoriasis Area Severity Index Score (PASI) 100 at Week 12 | 1 Participants |
| Part II - BI 200 mg Twice Daily, 400 mg Total (Fed) | Number of Patients Who Achieved Psoriasis Area Severity Index Score (PASI) 100 at Week 12 | 2 Participants |
p-value: 0.470195% CI: [-2.4, 7.5]Chi-squared
p-value: 0.309195% CI: [-1.8, 11.8]Chi-squared
Comparison: The 95% confidence interval for the unadjusted absolute difference in proportion (%) between active group and placebo group was estimated by Chi-square method. As pre-specified, no hypothesis testing was carried out for Part 2 of this trial and no p-values were provided.95% CI: [-2.2, 6.8]
Comparison: The 95% confidence interval for the unadjusted absolute difference in proportion (%) between active group and placebo group was estimated by Chi-square method. As pre-specified, no hypothesis testing was carried out for Part 2 of this trial and no p-values were provided.95% CI: [-2.2, 7]
Secondary
Number of Patients Who Achieved Psoriasis Area Severity Index Score (PASI) 50 at Week 12
Number of patients who achieved Psoriasis Area Severity Index score (PASI) 50 at week 12. The PASI is a tool which provides a numeric scoring for patients overall psoriasis disease state, ranging from 0 to 72. It is a linear combination of percent of surface area of skin that is affected and the severity of erythema, infiltration, and desquamation over four body regions. Higher scores indicating higher severity, while a score of 0 indicates no disease. PASI 50 is based on the percent reduction from baseline, generally summarized as a dichotomous outcome based on achieving over an 50% reduction. No hypothesis testing was planned or carried out for Part II.
Time frame: Assesment at week 12 of treatment
Population: Full Analysis Set (FAS): The FAS includes all patients who received at least 1 dose of trial medication and provided baseline and at least 1 post-randomisation measurement of Psoriasis Area Severity Index (PASI). Subjects with missing data for subsequent visits were included but those entries were imputed as failures.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Part I - Placebo (Fasted) | Number of Patients Who Achieved Psoriasis Area Severity Index Score (PASI) 50 at Week 12 | 1 Participants |
| Part I - BI 25 mg (Fasted) | Number of Patients Who Achieved Psoriasis Area Severity Index Score (PASI) 50 at Week 12 | 2 Participants |
| Part I - BI 50 mg (Fasted) | Number of Patients Who Achieved Psoriasis Area Severity Index Score (PASI) 50 at Week 12 | 10 Participants |
| Part I - BI 100 mg (Fasted) | Number of Patients Who Achieved Psoriasis Area Severity Index Score (PASI) 50 at Week 12 | 8 Participants |
| Part I - BI 200 mg (Fasted) | Number of Patients Who Achieved Psoriasis Area Severity Index Score (PASI) 50 at Week 12 | 20 Participants |
| Part II - Placebo (Fed) | Number of Patients Who Achieved Psoriasis Area Severity Index Score (PASI) 50 at Week 12 | 1 Participants |
| Part II - BI 400 mg Once Daily (Fed) | Number of Patients Who Achieved Psoriasis Area Severity Index Score (PASI) 50 at Week 12 | 24 Participants |
| Part II - BI 200 mg Twice Daily, 400 mg Total (Fed) | Number of Patients Who Achieved Psoriasis Area Severity Index Score (PASI) 50 at Week 12 | 19 Participants |
p-value: 195% CI: [-11.7, 11.7]Chi-squared
p-value: 0.05495% CI: [3.9, 37.3]Chi-squared
p-value: 0.116795% CI: [-0.4, 31.4]Chi-squared
p-value: 0.000695% CI: [26.8, 63.2]Chi-squared
Comparison: The 95% confidence interval for the unadjusted absolute difference in proportion (%) between active group and placebo group was estimated by Chi-square method. As pre-specified, no hypothesis testing was carried out for Part 2 of this trial and no p-values were provided.95% CI: [22, 69.6]
Comparison: The 95% confidence interval for the unadjusted absolute difference in proportion (%) between active group and placebo group was estimated by Chi-square method. As pre-specified, no hypothesis testing was carried out for Part 2 of this trial and no p-values were provided.95% CI: [11.3, 59.2]
Secondary
Number of Patients Who Achieved Psoriasis Area Severity Index Score (PASI) 75 at Weeks 16, 20, and 24
Number of patients who achieved Psoriasis Area Severity Index score (PASI) 75 at weeks 16, 20 and 24. The PASI is a tool which provides a numeric scoring for patients overall psoriasis disease state, ranging from 0 to 72. It is a linear combination of percent of surface area of skin that is affected and the severity of erythema, infiltration, and desquamation over four body regions. Higher scores indicating higher severity, while a score of 0 indicates no disease. PASI 75 is based on the percent reduction from baseline, generally summarized as a dichotomous outcome based on achieving over an 75% reduction.
Time frame: Assesment at week 16, 20 and 24 of treatment
Population: Full Analysis Set (FAS): The FAS includes all patients who received at least 1 dose of trial medication and provided baseline and at least 1 post-randomisation measurement of Psoriasis Area Severity Index (PASI). Subjects with missing data for subsequent visits were included but those entries were imputed as failures. Subjects with missing data for subsequent visits were included but those entries were imputed as failures.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part I - Placebo (Fasted) | Number of Patients Who Achieved Psoriasis Area Severity Index Score (PASI) 75 at Weeks 16, 20, and 24 | Week 16 | 0 Participants |
| Part I - Placebo (Fasted) | Number of Patients Who Achieved Psoriasis Area Severity Index Score (PASI) 75 at Weeks 16, 20, and 24 | Week 24 | 0 Participants |
| Part I - Placebo (Fasted) | Number of Patients Who Achieved Psoriasis Area Severity Index Score (PASI) 75 at Weeks 16, 20, and 24 | Week 20 | 0 Participants |
| Part I - BI 25 mg (Fasted) | Number of Patients Who Achieved Psoriasis Area Severity Index Score (PASI) 75 at Weeks 16, 20, and 24 | Week 20 | 2 Participants |
| Part I - BI 25 mg (Fasted) | Number of Patients Who Achieved Psoriasis Area Severity Index Score (PASI) 75 at Weeks 16, 20, and 24 | Week 16 | 1 Participants |
| Part I - BI 25 mg (Fasted) | Number of Patients Who Achieved Psoriasis Area Severity Index Score (PASI) 75 at Weeks 16, 20, and 24 | Week 24 | 2 Participants |
| Part I - BI 50 mg (Fasted) | Number of Patients Who Achieved Psoriasis Area Severity Index Score (PASI) 75 at Weeks 16, 20, and 24 | Week 20 | 3 Participants |
| Part I - BI 50 mg (Fasted) | Number of Patients Who Achieved Psoriasis Area Severity Index Score (PASI) 75 at Weeks 16, 20, and 24 | Week 16 | 1 Participants |
| Part I - BI 50 mg (Fasted) | Number of Patients Who Achieved Psoriasis Area Severity Index Score (PASI) 75 at Weeks 16, 20, and 24 | Week 24 | 4 Participants |
| Part I - BI 100 mg (Fasted) | Number of Patients Who Achieved Psoriasis Area Severity Index Score (PASI) 75 at Weeks 16, 20, and 24 | Week 16 | 5 Participants |
| Part I - BI 100 mg (Fasted) | Number of Patients Who Achieved Psoriasis Area Severity Index Score (PASI) 75 at Weeks 16, 20, and 24 | Week 24 | 4 Participants |
| Part I - BI 100 mg (Fasted) | Number of Patients Who Achieved Psoriasis Area Severity Index Score (PASI) 75 at Weeks 16, 20, and 24 | Week 20 | 4 Participants |
| Part I - BI 200 mg (Fasted) | Number of Patients Who Achieved Psoriasis Area Severity Index Score (PASI) 75 at Weeks 16, 20, and 24 | Week 20 | 13 Participants |
| Part I - BI 200 mg (Fasted) | Number of Patients Who Achieved Psoriasis Area Severity Index Score (PASI) 75 at Weeks 16, 20, and 24 | Week 16 | 11 Participants |
| Part I - BI 200 mg (Fasted) | Number of Patients Who Achieved Psoriasis Area Severity Index Score (PASI) 75 at Weeks 16, 20, and 24 | Week 24 | 14 Participants |
p-value: 0.475895% CI: [-2.3, 7.3]Chi-squared
p-value: 0.470195% CI: [-2.4, 7.5]Chi-squared
p-value: 0.094295% CI: [2.3, 23.3]Chi-squared
p-value: 0.009595% CI: [13.7, 41.3]Chi-squared
p-value: 0.309195% CI: [-1.8, 11.8]Chi-squared
p-value: 0.20395% CI: [-0.7, 16.1]Chi-squared
p-value: 0.13895% CI: [0.7, 19.8]Chi-squared
p-value: 0.00495% CI: [18, 47]Chi-squared
p-value: 0.13895% CI: [0.7, 19.8]Chi-squared
p-value: 0.002595% CI: [20.2, 49.8]Chi-squared
Secondary
Number of Patients Who Achieved Psoriasis Area Severity Index Score (PASI) 90 at Week 12
Number of patients who achieved Psoriasis Area Severity Index score (PASI) 90 at week 12. The PASI is a tool which provides a numeric scoring for patients overall psoriasis disease state, ranging from 0 to 72. It is a linear combination of percent of surface area of skin that is affected and the severity of erythema, infiltration, and desquamation over four body regions. Higher scores indicating higher severity, while a score of 0 indicates no disease. PASI 90 is based on the percent reduction from baseline, generally summarized as a dichotomous outcome based on achieving over an 90% reduction. No statistical comparisons were planned or carried out for Part 2 of the trial. Statistical analysis could not be performed for arms with 0 participants reaching PASI 90.
Time frame: Assesment at week 12 of treatment
Population: Full Analysis Set (FAS): The FAS includes all patients who received at least 1 dose of trial medication and provided baseline and at least 1 post-randomisation measurement of Psoriasis Area Severity Index (PASI). Subjects with missing data for subsequent visits were included but those entries were imputed as failures.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Part I - Placebo (Fasted) | Number of Patients Who Achieved Psoriasis Area Severity Index Score (PASI) 90 at Week 12 | 0 Participants |
| Part I - BI 25 mg (Fasted) | Number of Patients Who Achieved Psoriasis Area Severity Index Score (PASI) 90 at Week 12 | 0 Participants |
| Part I - BI 50 mg (Fasted) | Number of Patients Who Achieved Psoriasis Area Severity Index Score (PASI) 90 at Week 12 | 2 Participants |
| Part I - BI 100 mg (Fasted) | Number of Patients Who Achieved Psoriasis Area Severity Index Score (PASI) 90 at Week 12 | 1 Participants |
| Part I - BI 200 mg (Fasted) | Number of Patients Who Achieved Psoriasis Area Severity Index Score (PASI) 90 at Week 12 | 7 Participants |
| Part II - Placebo (Fed) | Number of Patients Who Achieved Psoriasis Area Severity Index Score (PASI) 90 at Week 12 | 0 Participants |
| Part II - BI 400 mg Once Daily (Fed) | Number of Patients Who Achieved Psoriasis Area Severity Index Score (PASI) 90 at Week 12 | 4 Participants |
| Part II - BI 200 mg Twice Daily, 400 mg Total (Fed) | Number of Patients Who Achieved Psoriasis Area Severity Index Score (PASI) 90 at Week 12 | 2 Participants |
p-value: 0.302895% CI: [-1.8, 12.1]Chi-squared
p-value: 0.470195% CI: [-2.4, 7.5]Chi-squared
p-value: 0.046595% CI: [5.7, 29.3]Chi-squared
Comparison: The 95% confidence interval for the unadjusted absolute difference in proportion (%) between active group and placebo group was estimated by Chi-square method. As pre-specified, no hypothesis testing was carried out for Part 2 of this trial and no p-values were provided.95% CI: [0.6, 18]
Comparison: The 95% confidence interval for the unadjusted absolute difference in proportion (%) between active group and placebo group was estimated by Chi-square method. As pre-specified, no hypothesis testing was carried out for Part 2 of this trial and no p-values were provided.95% CI: [-1.7, 11.2]
Secondary
Overall Change From Baseline in Psoriasis Symptoms Evaluated Using the Total Score of the Psoriasis Symptoms Scale (PSS) at Week 12
Overall change from baseline in psoriasis symptoms evaluated using the total score of the Psoriasis Symptoms Scale (PSS) at Week 12. The PSS is a four-item patient-reported outcome (PRO) instrument that assesses the severity of psoriasis symptoms in patients with moderate to severe psoriasis. The symptoms included are: pain, redness, itching and burning from psoriasis. Current symptom severity is assessed for a 24 hour recall period using a 5-point verbal rating scale, the PSS score ranges from 0 (none) to 4 (very severe). The symptom scores are added to an unweighted total score (range: 0 to 16). Presented 'Mean' values are actually 'Adjusted Mean'. No hypothesis testing was planned or carried out for Part II.
Time frame: Assesment at week 12 of treatment
Population: Full Analysis Set (FAS): All patients who received at least 1 dose of trial medication and provided a baseline and at least 1 postrandomisation measurement of PASI. Only participants with non-missing values are reported.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Part I - Placebo (Fasted) | Overall Change From Baseline in Psoriasis Symptoms Evaluated Using the Total Score of the Psoriasis Symptoms Scale (PSS) at Week 12 | -0.4 Total score | Standard Error 1 |
| Part I - BI 25 mg (Fasted) | Overall Change From Baseline in Psoriasis Symptoms Evaluated Using the Total Score of the Psoriasis Symptoms Scale (PSS) at Week 12 | 0.1 Total score | Standard Error 0.7 |
| Part I - BI 50 mg (Fasted) | Overall Change From Baseline in Psoriasis Symptoms Evaluated Using the Total Score of the Psoriasis Symptoms Scale (PSS) at Week 12 | 0.2 Total score | Standard Error 0.7 |
| Part I - BI 100 mg (Fasted) | Overall Change From Baseline in Psoriasis Symptoms Evaluated Using the Total Score of the Psoriasis Symptoms Scale (PSS) at Week 12 | 2.3 Total score | Standard Error 0.7 |
| Part I - BI 200 mg (Fasted) | Overall Change From Baseline in Psoriasis Symptoms Evaluated Using the Total Score of the Psoriasis Symptoms Scale (PSS) at Week 12 | 3.6 Total score | Standard Error 0.7 |
| Part II - Placebo (Fed) | Overall Change From Baseline in Psoriasis Symptoms Evaluated Using the Total Score of the Psoriasis Symptoms Scale (PSS) at Week 12 | 0.3 Total score | Standard Error 1.2 |
| Part II - BI 400 mg Once Daily (Fed) | Overall Change From Baseline in Psoriasis Symptoms Evaluated Using the Total Score of the Psoriasis Symptoms Scale (PSS) at Week 12 | 3.4 Total score | Standard Error 0.6 |
| Part II - BI 200 mg Twice Daily, 400 mg Total (Fed) | Overall Change From Baseline in Psoriasis Symptoms Evaluated Using the Total Score of the Psoriasis Symptoms Scale (PSS) at Week 12 | 3.3 Total score | Standard Error 0.6 |
p-value: 0.700895% CI: [-1.9, 2.8]Mixed Models Analysis
p-value: 0.626895% CI: [-1.8, 3]Mixed Models Analysis
p-value: 0.026695% CI: [0.3, 5.1]Mixed Models Analysis
p-value: 0.000995% CI: [1.7, 6.3]Mixed Models Analysis
95% CI: [0.4, 5.8]
95% CI: [0.4, 5.8]